Recombinant Human FGF3 protein

Fibroblast Growth Factor 3 (FGF3) is a member of the FGF family, a group of signaling proteins involved in diverse biological processes such as cell proliferation, differentiation, angiogenesis, and embryonic development. Initially identified through homology with other FGFs, FGF3 plays critical roles in tissue repair, organogenesis, and patterning during embryogenesis. It is particularly associated with craniofacial development, inner ear morphogenesis, and hair follicle cycling. Dysregulation of FGF3 has been linked to developmental disorders and cancers, including breast and thyroid carcinomas, underscoring its importance in both normal physiology and disease.

Recombinant FGF3 protein is engineered using genetic recombination techniques, typically expressed in prokaryotic (e.g., E. coli) or eukaryotic systems (e.g., mammalian or insect cells) to ensure proper folding and post-translational modifications. This bioengineered form retains the biological activity of native FGF3. enabling researchers to study its mechanisms without relying on animal-derived sources. Its production involves cloning the FGF3 gene into expression vectors, followed by purification via chromatography methods like affinity or ion-exchange.

In research, recombinant FGF3 is used to investigate signaling pathways, particularly its interaction with FGF receptors (FGFRs) and heparan sulfate proteoglycans, which are essential for signal transduction. It also serves as a tool in regenerative medicine, aiding studies on tissue repair, stem cell differentiation, and organoid development. Therapeutic applications are being explored, though challenges like stability, delivery, and off-target effects remain. Overall, recombinant FGF3 provides a controlled, scalable resource for advancing both basic science and translational research in developmental biology and oncology.